GAIN THERAPEUTICS, INC Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
GAIN THERAPEUTICS, INC (GANX) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$117.04 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- GAIN THERAPEUTICS, INC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was $24.59K, a 77.55% decline year-over-year.
- GAIN THERAPEUTICS, INC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $109.53K.
- GAIN THERAPEUTICS, INC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$442.50K, a 1251.69% decline year-over-year.
- GAIN THERAPEUTICS, INC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $38.42K.
- GAIN THERAPEUTICS, INC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $474.03K.
- GAIN THERAPEUTICS, INC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$527.17K, a 207.94% decline from fiscal 2023.
- GAIN THERAPEUTICS, INC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $488.40K.
- GAIN THERAPEUTICS, INC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$23.80K, a 123.61% decline from fiscal 2021.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$117.04K 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $24.59K 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $474.03K 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $376.27K 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $369.61K 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | $109.53K 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | -$527.17K 10-K · filed 2026-03-26 | |||
| 2024-09-30 | -$46.58K 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | -$429.38K 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$442.50K 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $488.40K 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $5.16K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $149.73K 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $38.42K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$23.80K 10-K · filed 2024-03-26 | |||
| 2022-09-30 | -$249.85K 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$143.88K 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$49.32K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $100.78K 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $36.27K 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $1.82K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |